Topic: age-related macular degeneration
Kodiak Sciences sold a capped 4.5% royalty on its eye disease drug that could rival Eylea in exchange for $225 million in development funding.
While pivoting to gene therapies, microcap Iveric bio (once Ophthotech) has posted positive data from its key eye drug Zimura (avacincaptad pegol).
Opthea tested its drug in combination with Lucentis, finding that the combo bested Lucentis alone at improving vision and reducing scarring in the retina.
Researchers are hoping to one day circumvent the retinas of people with age-related macular degeneration and progressive blindness.
The phase 1b study tested KSI-301 in age-related macular degeneration, diabetic macular edema or macular edema from retinal vein occlusion.
The resumption follows modifications to the production process to cut the risk of the noninfectious inflammation that triggered the halt.
NIH scientists pinpointed targets at six different “loci,” or genomic regions, that are related to the development of age-related macular degeneration.
The National Eye Institute's stem cell-based therapy safely prevented blindness in animal models of age-related macular degeneration.
A collaboration between Unity Biotech and Ascentage Pharma has yielded a development candidate to treat age-related diseases of the eye.
Stealth BioTherapeutics filed to raise up to $86 million in its Nasdaq IPO, funding that will push its lead asset through the clinic in two indications.